In a 40-week clinical trial spanning the United States, Mexico, and India, a new drug called retatrutide achieved something that has eluded existing obesity and diabetes treatments: it simultaneously slashed blood sugar levels and body weight in adults with type 2 diabetes who couldn't control their condition through diet and exercise alone.
Type 2 diabetes has become one of the world's fastest-growing health challenges, affecting more than 589 million adults globally, with cases expected to keep climbing. The condition develops when the body becomes less responsive to insulin, and the pancreas can no longer produce enough of the hormone to maintain healthy blood sugar levels. Over time, high blood sugar damages blood vessels throughout the body, increasing the risk of serious complications including heart disease. Current medical guidelines suggest that achieving an HbA1c below 6.5% alongside weight loss of at least 10% may help prevent these dangers.
For years, GLP-1 drugs have transformed treatment for obesity and type 2 diabetes by mimicking a hormone that helps regulate blood sugar, slows digestion, and curbs appetite. But retatrutide represents the next wave: it belongs to an emerging class called GLP-3 agonists that target three hormone pathways simultaneously—GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon—to amplify metabolic benefits. While popular GLP-1 medications act on a single hormone pathway, this triple-action approach addresses both blood sugar control and weight loss at once.
The Phase III trial, called TRANSCEND-T2D, enrolled 537 adults across 48 sites. Participants were randomly assigned to receive once-weekly injections of retatrutide at doses of 4 mg, 9 mg, or 12 mg, or a placebo. The results, published in The Lancet, were striking. Nearly nine out of 10 participants who received retatrutide achieved an HbA1c below 7.0%—the standard target for diabetes control. Even more remarkably, up to 40% of those who received the drug pushed their levels below 5.7%, entering the normal range. Participants also saw significant drops in fasting serum glucose levels, improvements in cholesterol and blood pressure, and reductions in waist circumference.
The weight loss results were particularly impressive. Participants who received the highest dose of retatrutide lost an average of 15.3% of their body weight over the 40 weeks, while those on mid-range doses lost 11.5%. In stark contrast, the placebo group lost just 2.6% of their body weight. By the end of the trial, participants were still losing weight, suggesting the drug's effects were sustained.
This represents a significant advancement because existing GLP-1 drugs, while helpful, are more effective at causing weight loss in people without diabetes than in those with the condition. Retatrutide appears to overcome this limitation by targeting multiple pathways that work together: GIP boosts insulin release and improves how the body's cells handle sugar, while glucagon encourages the body to burn more energy and process fat more efficiently.
As diabetes rates continue to climb globally, retatrutide offers hope that next-generation therapies can deliver even greater improvements in metabolic health. The drug's ability to achieve both targets—better blood sugar control and significant weight loss—in a single once-weekly injection could transform how doctors treat millions of people struggling with one of the world's most pressing health challenges.